Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 3Phase 2 2Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × 5-aminolevulinic acid hexyl ester × Clear all
NCT00785694 2015-04-24

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

GE Healthcare

Phase 4 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡